Robert Harrington to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Robert Harrington has written about Dose-Response Relationship, Drug.
Connection Strength
1.104
-
Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. Am Heart J. 2018 04; 198:84-90.
Score: 0.109
-
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation. 2016 Dec 13; 134(24):1918-1930.
Score: 0.101
-
Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. Am Heart J. 2016 Oct; 180:22-8.
Score: 0.099
-
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). Am J Cardiol. 2015 May 15; 115(10):1325-32.
Score: 0.090
-
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). Am J Cardiol. 2014 Mar 15; 113(6):936-44.
Score: 0.083
-
Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. Am Heart J. 2010 Nov; 160(5):795-803.e2.
Score: 0.067
-
Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. Thromb Haemost. 2004 Dec; 92(6):1182-93.
Score: 0.044
-
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation. 2002 May 21; 105(20):2385-91.
Score: 0.037
-
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10?854 patients from the CHAMPION PHOENIX trial. Eur Heart J. 2018 12 07; 39(46):4112-4121.
Score: 0.029
-
Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). Am J Cardiol. 2017 Oct 01; 120(7):1043-1048.
Score: 0.026
-
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. Am Heart J. 2017 Jun; 188:147-155.
Score: 0.026
-
Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. JAMA Cardiol. 2017 02 01; 2(2):127-135.
Score: 0.026
-
Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS. Int J Cardiol. 2017 Apr 01; 232:264-270.
Score: 0.026
-
Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial. Am Heart J. 2016 Dec; 182:62-71.
Score: 0.025
-
Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. Eur Heart J Acute Cardiovasc Care. 2018 Mar; 7(2):158-165.
Score: 0.025
-
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart. 2016 Apr; 102(8):617-25.
Score: 0.024
-
Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. Am Heart J. 2015 Apr; 169(4):531-8.
Score: 0.022
-
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). Am Heart J. 2014 Oct; 168(4):588-96.
Score: 0.021
-
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Am J Cardiol. 2014 Sep 01; 114(5):665-73.
Score: 0.021
-
Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. Am Heart J. 2013 Oct; 166(4):723-8.
Score: 0.020
-
Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant. 2014 Apr; 29(4):833-42.
Score: 0.020
-
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J. 2012 May; 163(5):768-776.e2.
Score: 0.018
-
Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J. 2012 Feb; 163(2):182-90.e4.
Score: 0.018
-
Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). Am J Cardiol. 2011 Dec 01; 108(11):1542-6.
Score: 0.018
-
Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. Am Heart J. 2010 Dec; 160(6):1056-64, 1064.e2.
Score: 0.017
-
Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost. 2010 Nov; 104(5):976-83.
Score: 0.016
-
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009 Jun 09; 119(22):2877-85.
Score: 0.015
-
Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome. Am Heart J. 2008 Jul; 156(1):177-84.
Score: 0.014
-
Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation. 2008 Jan 15; 117(2):192-9.
Score: 0.014
-
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation. 2006 Dec 05; 114(23):2490-7.
Score: 0.013
-
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003 Jul 29; 108(4):399-406.
Score: 0.010
-
Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol. 2003 Feb 05; 41(3):386-93.
Score: 0.010